MedTrace Logo

High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication

NCT01888237 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2015-04-10

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy between 1-day high dose PPI-based triple therapy vs. 10-day sequential therapy for Helicobacter pylori eradication in functional dyspepsia patients.

Conditions

  • Dyspepsia
  • Helicobacter-associated Gastritis
  • Stomach Disorders

Interventions

DRUG

Double dose of PPI

Lansoprasole (30mg) 2 tab oral BID

DRUG

sequence of drug use

lansoprazole 30 mg b.d. for 10 days amoxicillin 1000 mg b.d. (day 1 to day 5) metronidazole 400 mg b.d. (day 6-day 10) and clarithromycin 500 mg b.d. (day 6-day 10)

Sponsors & Collaborators

  • Takeda Pharmaceuticals International, Inc.

    collaborator INDUSTRY

  • Mahidol University

    lead OTHER

Principal Investigators

  • monthira maneerattanaporn · Division of gastroenterology, Department of Medicine, Siriraj hospital 2, Pran-nok, Bangkoknoi, Bangkok, Thailand, Mahidol University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-08-31
Completion
2014-09-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01888237 on ClinicalTrials.gov